Weitz Partners III Opportunity Fund Added Bio-Techne Corporation (TECH) to its Portfolio
Weitz Investment Management, an investment management firm, released its “Partners III Opportunity Fund” fourth-quarter 2024 investor letter.
Posts Tagged ‘NASDAQ:TECH’
Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Call Transcript February 5, 2025Bio-Techne Corporation beats earnings expectations.
Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Call Transcript October 30, 2024Bio-Techne Corporation beats earnings expectations.
Here’s What Dragged Bio-Techne Corporation (TECH)?
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” second quarter 2024 investor letter.
Bio-Techne Corporation (NASDAQ:TECH) Q4 2024 Earnings Call Transcript
Operator: [Call Starts Abruptly] Call for the Fourth Quarter of Fiscal Year 2024.
Multiple Headwinds Dragged Bio-Techne Corp. (TECH) in Q1
Conestoga Capital Advisors, an asset management company, released its “Mid-Cap Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Bio-Techne Corporation (TECH) Declined on Weak Q4 Results
Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript
Bio-Techne Corporation beats earnings expectations. Reported EPS is $0.48, expectations were $0.46.
Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript
Bio-Techne Corporation beats earnings expectations. Reported EPS is $0.48, expectations were $0.46.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
What Makes Bio-Techne Corporation (TECH) an Investment Bet?
Polen Capital, an investment management company, released its “Polen U.S. SMID Company Growth Strategy” fourth-quarter 2023 investor letter.
Bio-Techne Corporation (NASDAQ:TECH) Q2 2024 Earnings Call Transcript
Bio-Techne Corporation misses on earnings expectations. Reported EPS is $0.4 EPS, expectations were $0.42.
Should You Hold Bio-Techne Corporation (TECH) For the Long Term?
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2023 investor letter.
Bio-Techne Corporation (NASDAQ:TECH) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2024.
Various Headwinds Pressured Bio-Techne Corporation (TECH) Shares in Q3
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here.
Bio-Techne Corporation (NASDAQ:TECH) Q4 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Fourth Quarter of Fiscal Year 2023.
Should You Hold Bio-Techne Corp. (TECH)?
Conestoga Capital Advisors, an asset management company, released its “Mid Cap Strategy” first-quarter 2023 investor letter. A copy of the same can be downloaded here.
Bio-Techne Corporation (NASDAQ:TECH) Q3 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Bio-Techne Corp Third Quarter Fiscal 2023 Earnings Call. All participants will be in a listen-only mode.
Here’s Why Bio-Techne Corporation (TECH) Declined in Q1
Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Bio-Techne Corporation (NASDAQ:TECH) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2023.
Do You Think Bio-Techne Corporation (TECH) Has a Positive Long-Term Trend?
Jackson Square Partners, an investment management firm, released its “SMID-Cap Growth” Q3 2022 investor letter. A copy of the same can be downloaded here.
Should You Invest in Bio-Techne Corporation (TECH)?
Conestoga Capital Advisors, an asset management company, released its “Conestoga Mid Cap Growth Fund” third-quarter investor letter.
Should You Invest in Bio-Techne Corporation (TECH)?
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2022 investor letter.
Can Bio-Techne Corporation (TECH) Still Bounce Back?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Baron Funds: “Bio-Techne (TECH) is a Stable Business”
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here.
Baron Funds: “Bio-Techne (TECH) Can Still Generate Strong Revenue Growth”
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Is it a Wise Decision to Keep Your Bio-Techne (TECH) Position?
Aristotle Capital Management, an independent/employee-owned investment management organization, published its “Aristotle Core Equity” first quarter 2022 investor letter – ...
Did The Smart Money Get Bio-Techne Corporation (TECH) Right?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy...
10 Stocks Drawing Attention on Earnings Reports
In this article, we will take a look at the 10 stocks drawing attention on earnings reports.
Hedge Funds Have Never Been This Bullish On Bio-Techne Corporation (TECH)
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive...
Here’s What Makes Bio-Techne Corp. (TECH) A Great Stock Investment
Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Funds Are Buying Bio-Techne Corporation (TECH)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Here’s Why Baron Funds Remains Confident in Bio-Techne Corporation (TECH)
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Funds Are Souring On Bio-Techne Corporation (TECH)
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell...
10 Best Stocks to Buy in 2021 According to Louis Navellier
In this article we will take a look at 10 Best Stocks to Buy in 2021 According to Louis Navellier.
Here’s Why Baron Funds Became Bullish in Bio-Techne Corp. (TECH)
Baron Funds, an asset management firm, published its “Baron Growth Fund” first quarter 2021 investor letter – a copy of which can be downloaded here.
Is Bio-Techne (TECH) Stock A Buy or Sell?
At Insider Monkey, we pore over the filings of nearly 887 top investment firms every quarter, a process we have now completed for the latest reporting period.
Is It Too Late to Buy Bio-Techne (TECH) Stock?
Baron Asset Fund recently published its first-quarter commentary – a copy of which can be downloaded here.
Is Bio-Techne Corporation (TECH) A Smart Long-Term Buy?
Alger, an investment management firm, published its “Alger Small Cap Focus Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. During the...
Is Bio-Techne (TECH) A Smart Long-Term Buy?
Mairs & Power, an investment management firm, published its fourth-quarter 2020 ‘Growth Fund’ Investor Letter – a copy of which can be downloaded here.
Is TECH A Good Stock To Buy According To Hedge Funds?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell...
Is Bio-Techne Corp (TECH) a Smart Long-term Buy?
Baron Asset Fund recently published its third-quarter commentary – a copy of which can be downloaded here.
Do Hedge Funds Really Like Bio-Techne Corporation (TECH)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Did Hedge Funds Make The Right Call On Bio-Techne Corporation (TECH) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy...
Hedge Funds Are Done Buying Bio-Techne Corporation (TECH)?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Hedge Funds Have Never Been This Bullish On Bio-Techne Corporation (TECH)
We hate to say this but, we told you so.
Is Bio-Techne Corporation (TECH) A Good Stock To Buy?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Hedge Funds Have Never Been More Bullish On Bio-Techne Corporation (TECH)
A whopping number of 13F filings filed with U.S.
Here’s What Hedge Funds Think About Bio-Techne Corporation (TECH)
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips.
Hedge Funds Dropped The Ball On Bio-Techne Corporation (TECH)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in...
